Myomo (MYO) Free Cash Flow Growth (3y) (2019 - 2025)

Myomo (MYO) Free Cash Flow Growth (3y) (2019 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (3y) (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn 6.28%
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 9.63%
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn 0.05%
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn 29.36%
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -27.72%
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 77.20%
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn -29.89%
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn -0.27%
10 Myomo 43.43 Mn 24.46 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 -0.91%
Jun 30, 2025 -55.33%
Mar 31, 2025 -12.16%
Dec 31, 2024 49.46%
Sep 30, 2024 6.85%
Jun 30, 2024 17.31%
Mar 31, 2024 -15.29%
Dec 31, 2023 -27.63%
Sep 30, 2023 0.99%
Jun 30, 2023 56.52%
Mar 31, 2023 8.78%
Dec 31, 2022 2.45%
Sep 30, 2022 -6.93%
Jun 30, 2022 -5.24%
Mar 31, 2022 8.78%
Dec 31, 2021 9.47%
Sep 30, 2021 3.76%
Jun 30, 2021 -15.09%
Mar 31, 2021 2.54%
Dec 31, 2020 10.50%